Pilloxas enables customers to be innovative and accelerate patient-centered learning through a cloud-hosted solution.
FREMONT, CA: Pilloxa, a digital health firm, launches a cloud-hosted solution that enables pharmaceutical companies and medical research teams to engage and learn from patients. By developing branded programs within Pilloxas' patient-facing mobile app, the customer can provide a customized experience to patients at a fraction of the industry-standard cost while also generating valuable data insights. In addition, Pilloxa’s new product offering disrupts the market by establishing a standardized pricing structure that accommodates patient support programs and clinical research budgets of all sizes.
Pilloxas enables customers to take on the role of innovators and accelerate patient-centric learning. The customer selects the modules for their own patient-facing mobile app program through the platform, including medication support, adherence dashboards, and even interactive learning material about the medication and treatment journey. Additionally, the customer supplies the content, enabling them to brand the material and develop valuable relationships with patients. If a customer wishes to assist patients taking medication in pill form with adherence, Pilloxas' original smart pillbox can be connected to the app.
“Creating your own program within the integrated Pilloxa mobile app establishes a link to patients to provide value and collect data for driving innovation,” explains Pilloxa CEO Francesco Mazzotta. “By analyzing engagement within the patient-facing app through Pilloxas web interface, the customer can iterate as often as they like by making changes to the app to deliver value and become the leading expert on their unique patient population. Furthermore, all patient functionality is always included, and new modules are constantly introduced to ensure patient value throughout the lifespan of the program.”
Pilloxa already has a strong collaborator network. Pharmaceutical partners include Bayer Pharmaceuticals in Sweden and Sandoz Pharmaceuticals in Scandinavia, while medical research partners include Oslo University, Karolinska University, and Hospital and Danderyd Hospital. Besides investments from top Swedish investor profiles, Pilloxa also received EU innovation funding.
Together with their new product offering, Pilloxa is also launching a new brand identity and website. The website contains an interactive pricing calculator and app visualizer for customers to play around with which solution best fits their needs and budget.
Speaking of the importance of unlocking Life Science's innovation potential, Pilloxa CEO Francesco Mazzotta further adds, “We have seen the need for innovation within the industry and the willingness of pharmaceutical companies and research institutions to facilitate, however, many blockers remain. Connecting apps with medication taking is no longer a question. It is about creating value for patients and delivering optimal health solutions. No company within healthcare will stay relevant without that. User response will be the guiding light to understand in which way to combine them on a case-by-case level, and the impact will be felt by all stakeholders involved within the patient journey.”